AzTrials
AzTrials

Sunscreen AgentsNCT02872194

Evaluation of the Stinging Potential of Products in Human Eyes

A study testing BAY987516, Y55-170, BAY987516, X72-151 and BAY987516, Y49-034 in people with Sunscreen Agents, run by Bayer at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study was to compare the human eye stinging potential of experimental formulas and an industry standard shampoo mixture. The study was conducted under the supervision of a Board Certified Ophthalmologist. The study design was a three cell, single blind study. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Sunscreen Agents
What is being tested?
BAY987516, Y55-170, BAY987516, X72-151 and BAY987516, Y49-034
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
21 participants
Where
1 siteUnited States
Study dates
5 Sep 2014to 6 Sep 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Male or female subjects, aged 18 to 65 years
  • No medical conditions of the eyes as determined by the subjects' medical history and confirmed by ophthalmologist
  • Subjects do not wear contact lenses or, if he/she does wear contact lenses, is willing to refrain from wearing these during the day of and day after the study
  • Subject is willing to have the test materials instilled into the eyes and follow all protocol requirements
  • Subject is willing to refrain from using false eyelashes of any type or any topical prescription, OTC or cosmetic products on their eyes, eyelids, eyelashes or the peri-orbital areas of the face on the day of the study.
  • Subjects should refrain from use of make-up on testing day

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Study site

    St. Petersburg, Florida, 33714

Other trials in United States

About this study

The objective of this study was to compare the human eye stinging potential of experimental formulas and an industry standard shampoo mixture. The study was conducted under the supervision of a Board Certified Ophthalmologist. The study design was a three cell, single blind study. Subjects were given the industry standard shampoo mixture in one eye and an exploratory sunscreen in the other as according to the randomization schedule.

Being tested
BAY987516, Y55-170, BAY987516, X72-151, BAY987516, Y49-034, Standard shampoo mixture (control)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BAY987516, Y55-170Drug

    10 uL in one eye

  • BAY987516, X72-151Drug

    10 uL in one eye

  • BAY987516, Y49-034Drug

    10 uL in one eye

  • Standard shampoo mixture (control)Drug

    10 uL in one eye

Study groups in NCT02872194
Study groupRoleWhat they receive
Suncare agent A + controlExperimentalApplication of control and test product into one of the subjects two eyes.
Receives: Drug: BAY987516, Y55-170; Drug: Standard shampoo mixture (control)
Suncare agent B + controlExperimentalApplication of control and test product into one of the subjects two eyes.
Receives: Drug: BAY987516, X72-151; Drug: Standard shampoo mixture (control)
Suncare agent C + controlExperimentalApplication of control and test product into one of the subjects two eyes.
Receives: Drug: BAY987516, Y49-034; Drug: Standard shampoo mixture (control)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Subjective discomfort in the eye was assessed based on questions by an Ophthalmologist to the subject using a 5-category intensity scale

    Measured: up to 24 hours after instillation

  2. Tearing/Lacrimation was assessed by the Ophthalmologist using a 5-category assessment score

    Measured: up to 24 hours after instillation

  3. Objective inflammation was assessed by the Ophthalmologist using a 5-category assessment score

    Measured: up to 24 hours after instillation

  4. Post installation eye effects were assessed using a 5-category intensity score

    Measured: up to 24 hours after instillation

Secondary outcomes (1)
  1. Number of adverse events as a measure of safety and tolerability

    Measured: at 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Aug 2016 (estimated)
  2. Study start5 Sep 2014
  3. Primary completion6 Sep 2014
  4. Study completion6 Sep 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Single group
Masking
Single blind
Who is masked
Participant
Enrolment
21 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02872194
Sponsor's protocol ID
17913
Status last verified
Dec 2018
First submitted
3 Aug 2016
Last updated
12 Dec 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing BAY987516, Y55-170, BAY987516, X72-151 and BAY987516, Y49-034 in people with Sunscreen Agents, run by Bayer at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Subjective discomfort in the eye was assessed based on questions by an Ophthalmologist to the subject using a 5-category intensity scale (time frame: up to 24 hours after instillation). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in